BioCentury | Aug 1, 2019
Distillery Therapeutics

A pyrrolopyrimidine-based TYRO3 inhibitor for primary effusion lymphoma

...the compound decreased tumor growth in a xenograft mouse model of PEL. Next steps by Meryx Inc....
...EXPERIMENTAL SYSTEM: In vitro ; patient samples; cell culture; mice LICENSING STATUS: Patented; licensed to Meryx Inc....
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...on M1 and M2 macrophages (Abstract No. 4081 , No. 1555 and No. 4556 ). Meryx Inc....
...lung cancer (NSCLC) ( No. 2192A , No. 3037 , No.1314 , No. 4765 ). Meryx...
...Hamilton, Canada Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), Cambridge, Mass. Meryx Inc....
BioCentury | Dec 17, 2015
Translation in Brief

Old PKIS, new probes

...Chemical Biology and Medicinal Chemistry at the university. Drewry is the head of chemistry at Meryx Inc....
BioCentury | May 5, 2014
Financial News

Meryx completes venture financing

Meryx Inc. , Chapel Hill, N.C. Business: Cancer Date completed: 4/28/14 Type: Venture financing Raised: $3.1 million Note: The company raised $3.1 million in an undisclosed venture round, according to an SEC filing. WIR Staff cancer...
BioCentury | Mar 13, 2014
Cover Story

Killer targets in metastasis

...North Carolina at Chapel Hill Eshelman School of Pharmacy . He also is cofounder of Meryx Inc....
...Germany Max Planck Institute of Biochemistry , Martinsried, Germany Medical University Innsbruck , Innsbruck, Austria Meryx Inc....
BioCentury | Dec 19, 2013
Distillery Therapeutics

Indication: Various

...doi:10.1038/scibx.2013.1400 Published online Dec. 19, 2013 Patented by The University of North Carolina; licensed to Meryx Inc....
BioCentury | Aug 22, 2013
Distillery Therapeutics

Indication: Cancer

...Published online Aug. 22, 2013 Patented by The University of North Carolina at Chapel Hill; Meryx Inc....
Items per page:
1 - 7 of 7
BioCentury | Aug 1, 2019
Distillery Therapeutics

A pyrrolopyrimidine-based TYRO3 inhibitor for primary effusion lymphoma

...the compound decreased tumor growth in a xenograft mouse model of PEL. Next steps by Meryx Inc....
...EXPERIMENTAL SYSTEM: In vitro ; patient samples; cell culture; mice LICENSING STATUS: Patented; licensed to Meryx Inc....
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...on M1 and M2 macrophages (Abstract No. 4081 , No. 1555 and No. 4556 ). Meryx Inc....
...lung cancer (NSCLC) ( No. 2192A , No. 3037 , No.1314 , No. 4765 ). Meryx...
...Hamilton, Canada Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK), Cambridge, Mass. Meryx Inc....
BioCentury | Dec 17, 2015
Translation in Brief

Old PKIS, new probes

...Chemical Biology and Medicinal Chemistry at the university. Drewry is the head of chemistry at Meryx Inc....
BioCentury | May 5, 2014
Financial News

Meryx completes venture financing

Meryx Inc. , Chapel Hill, N.C. Business: Cancer Date completed: 4/28/14 Type: Venture financing Raised: $3.1 million Note: The company raised $3.1 million in an undisclosed venture round, according to an SEC filing. WIR Staff cancer...
BioCentury | Mar 13, 2014
Cover Story

Killer targets in metastasis

...North Carolina at Chapel Hill Eshelman School of Pharmacy . He also is cofounder of Meryx Inc....
...Germany Max Planck Institute of Biochemistry , Martinsried, Germany Medical University Innsbruck , Innsbruck, Austria Meryx Inc....
BioCentury | Dec 19, 2013
Distillery Therapeutics

Indication: Various

...doi:10.1038/scibx.2013.1400 Published online Dec. 19, 2013 Patented by The University of North Carolina; licensed to Meryx Inc....
BioCentury | Aug 22, 2013
Distillery Therapeutics

Indication: Cancer

...Published online Aug. 22, 2013 Patented by The University of North Carolina at Chapel Hill; Meryx Inc....
Items per page:
1 - 7 of 7